US Stock Market Move | Q4 performance and this year's profit guidance exceeded expectations, Gilead Sciences, Inc. (GILD.US) rose over 8%

On Wednesday, Gilead Sciences, Inc. (GILD.US) rose over 8%, reaching a historical high of $104.08. On the news front, the company reported its fourth-quarter performance from last year, with revenue increasing by 6% year-on-year to $7.569 billion, surpassing market expectations of $7.14 billion; of which, sales of HIV drugs increased by 16% to $5.5 billion. Net profit rose by 25% year-on-year to $1.783 billion; adjusted earnings per share were $1.90, higher than the market's expectation of $1.70. In terms of guidance, the company expects sales to range between $28.2 billion and $28.6 billion this year, with market expectations at $28.42 billion.